PERK activation mitigates tau pathology in vitro and in vivo.

about

ER stress and the unfolded protein response in neurodegeneration.(off)Targeting UPR signaling: the race toward intervening ER proteostasis.An Overview on the Clinical Development of Tau-Based Therapeutics.

P2860

Q38653861-32750E88-CBEE-4DE0-A26D-53974E72F52C Q47271819-959C9457-CC41-4173-A5B8-ADCDD04E4FE2 Q52594209-3E17179B-F1B6-4AB1-A236-515228A36D9A

P2860

PERK activation mitigates tau pathology in vitro and in vivo.

Item

http://www.wikidata.org/entity/Q37672742

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

PERK activation mitigates tau pathology in vitro and in vivo.

@en

PERK activation mitigates tau pathology in vitro and in vivo.

@nl

type

Item

label

PERK activation mitigates tau pathology in vitro and in vivo.

@en

PERK activation mitigates tau pathology in vitro and in vivo.

@nl

altLabel

PERK activation mi ...... and in vivo

@en

PERK activation mitigates tau pathology

@en

prefLabel

PERK activation mitigates tau pathology in vitro and in vivo.

@en

PERK activation mitigates tau pathology in vitro and in vivo.

@nl

P1476

PERK activation mitigates tau pathology in vitro and in vivo.

@en

P2093

Anderson De Andrade

http://www.w3.org/2001/XMLSchema#string

Hong Xu

http://www.w3.org/2001/XMLSchema#string

Julius Bruch

http://www.w3.org/2001/XMLSchema#string

Peer-Hendrik Kuhn

http://www.w3.org/2001/XMLSchema#string

Thomas Arzberger

http://www.w3.org/2001/XMLSchema#string

Thomas W Rösler

http://www.w3.org/2001/XMLSchema#string

Ulrich Müller

http://www.w3.org/2001/XMLSchema#string

P2860

Sustained translational repression by eIF2α-P mediates prion neurodegeneration

Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival

Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (P

Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein

Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants

Enzymatic assembly of DNA molecules up to several hundred kilobases

Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice

A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress

Rapid alteration of protein phosphorylation during postmortem: implication in the study of protein phosphorylation

Mechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signalling

P304

371-384

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.15252/EMMM.201606664

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Konstanze F Winklhofer

Stefan F Lichtenthaler

Günter U Höglinger

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28148553

http://www.w3.org/2001/XMLSchema#string

P921

pathology

P932

5331260

http://www.w3.org/2001/XMLSchema#string

PERK activation mitigates tau pathology in vitro and in vivo.

about

P2860

P2860

PERK activation mitigates tau pathology in vitro and in vivo.

description

name

type

label

altLabel

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932